# Assessing the Minimal Important Difference (MID) of the Treatment Related Impact Measure-Adult Growth Hormone Deficiency (TRIM-AGHD)

> **NCT02005198** · — · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 98 (actual)

## Conditions studied

- Growth Hormone Disorder
- Adult Growth Hormone Deficiency

## Interventions

- **OTHER:** No treatment given

## Key facts

- **NCT ID:** NCT02005198
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 98 (ACTUAL)
- **Last updated:** 2017-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02005198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02005198, "Assessing the Minimal Important Difference (MID) of the Treatment Related Impact Measure-Adult Growth Hormone Deficiency (TRIM-AGHD)". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT02005198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*